Clinical studies on advantages and safety of visual laser ablation for patients with benign prostatic hyperplasia

Yasutomo Nasu, Toyohiko Watanabe, H. Kumon, H. Ohmori

Research output: Contribution to journalArticle

Abstract

Since 1992, we have been performing VLAP using a right-angle laser delivery system (Urolase) for BPH patients with significant underlying nonurological diseases such as diabetes mellitus, cardiovascular, pulmonary, and maligant diseases. Sufficient clinical results have been obtained without major complications during short-term and long-term observation. In this study, we discuss the clinical advantages and safety of VLAP, compared with TURP, through analysis of the clinical procedure for VLAP for patients treated with anticoagulant agents such as warfarin. In our study of 40 patients, 8 patients were treated with anticoagulants for cardiovascular disease. During the procedure and after the operation, no significant complications were encountered except for transient postoperative bleeding. The 8 patients who received simultaneous anticoagulant therapy also underwent TURP to draw a comparison. The time taken for the procedure and the volume of the blood loss were significantly reduced by VLAP. The hemostatic nature of YAG laser energy seems to result in a technical improvement over conventional TURP for patients undergoing anticoagulant therapy.

Original languageEnglish
JournalInternational Journal of Urology
Volume3
Issue numberSUPPL.
Publication statusPublished - 1996

Fingerprint

Transurethral Resection of Prostate
Prostatic Hyperplasia
Laser Therapy
Safety
Anticoagulants
Solid-State Lasers
Hemostatics
Warfarin
Clinical Studies
Blood Volume
Lung Diseases
Diabetes Mellitus
Lasers
Cardiovascular Diseases
Observation
Hemorrhage
Therapeutics

Keywords

  • Anticoagulant
  • BPH
  • Visual laser ablation of the prostate (VLAP)

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

@article{426ab411ea234e92a096d17f5cfc1fff,
title = "Clinical studies on advantages and safety of visual laser ablation for patients with benign prostatic hyperplasia",
abstract = "Since 1992, we have been performing VLAP using a right-angle laser delivery system (Urolase) for BPH patients with significant underlying nonurological diseases such as diabetes mellitus, cardiovascular, pulmonary, and maligant diseases. Sufficient clinical results have been obtained without major complications during short-term and long-term observation. In this study, we discuss the clinical advantages and safety of VLAP, compared with TURP, through analysis of the clinical procedure for VLAP for patients treated with anticoagulant agents such as warfarin. In our study of 40 patients, 8 patients were treated with anticoagulants for cardiovascular disease. During the procedure and after the operation, no significant complications were encountered except for transient postoperative bleeding. The 8 patients who received simultaneous anticoagulant therapy also underwent TURP to draw a comparison. The time taken for the procedure and the volume of the blood loss were significantly reduced by VLAP. The hemostatic nature of YAG laser energy seems to result in a technical improvement over conventional TURP for patients undergoing anticoagulant therapy.",
keywords = "Anticoagulant, BPH, Visual laser ablation of the prostate (VLAP)",
author = "Yasutomo Nasu and Toyohiko Watanabe and H. Kumon and H. Ohmori",
year = "1996",
language = "English",
volume = "3",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "SUPPL.",

}

TY - JOUR

T1 - Clinical studies on advantages and safety of visual laser ablation for patients with benign prostatic hyperplasia

AU - Nasu, Yasutomo

AU - Watanabe, Toyohiko

AU - Kumon, H.

AU - Ohmori, H.

PY - 1996

Y1 - 1996

N2 - Since 1992, we have been performing VLAP using a right-angle laser delivery system (Urolase) for BPH patients with significant underlying nonurological diseases such as diabetes mellitus, cardiovascular, pulmonary, and maligant diseases. Sufficient clinical results have been obtained without major complications during short-term and long-term observation. In this study, we discuss the clinical advantages and safety of VLAP, compared with TURP, through analysis of the clinical procedure for VLAP for patients treated with anticoagulant agents such as warfarin. In our study of 40 patients, 8 patients were treated with anticoagulants for cardiovascular disease. During the procedure and after the operation, no significant complications were encountered except for transient postoperative bleeding. The 8 patients who received simultaneous anticoagulant therapy also underwent TURP to draw a comparison. The time taken for the procedure and the volume of the blood loss were significantly reduced by VLAP. The hemostatic nature of YAG laser energy seems to result in a technical improvement over conventional TURP for patients undergoing anticoagulant therapy.

AB - Since 1992, we have been performing VLAP using a right-angle laser delivery system (Urolase) for BPH patients with significant underlying nonurological diseases such as diabetes mellitus, cardiovascular, pulmonary, and maligant diseases. Sufficient clinical results have been obtained without major complications during short-term and long-term observation. In this study, we discuss the clinical advantages and safety of VLAP, compared with TURP, through analysis of the clinical procedure for VLAP for patients treated with anticoagulant agents such as warfarin. In our study of 40 patients, 8 patients were treated with anticoagulants for cardiovascular disease. During the procedure and after the operation, no significant complications were encountered except for transient postoperative bleeding. The 8 patients who received simultaneous anticoagulant therapy also underwent TURP to draw a comparison. The time taken for the procedure and the volume of the blood loss were significantly reduced by VLAP. The hemostatic nature of YAG laser energy seems to result in a technical improvement over conventional TURP for patients undergoing anticoagulant therapy.

KW - Anticoagulant

KW - BPH

KW - Visual laser ablation of the prostate (VLAP)

UR - http://www.scopus.com/inward/record.url?scp=0030454848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030454848&partnerID=8YFLogxK

M3 - Article

VL - 3

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - SUPPL.

ER -